Market News AIOpen the app

FDMT stock news · 4D Molecular Therapeutics

Stories about 4D Molecular Therapeutics (FDMT) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for FDMT

Follow 4D Molecular Therapeutics (FDMT) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for FDMT
Free on the App Store and Google Play, or on the web.
  1. Nov 13, 2026, 5:37 PM ET · Market

    4D Molecular Therapeutics is giving 21,800 restricted stock units to a new employee as a signing bonus.

    Neutral

    4D Molecular Therapeutics granted 21,800 restricted stock units to one new employee outside its existing plans. This hiring award does not change the company's outlook.

  2. Nov 12, 2026, 4:18 PM ET · Market

    4D Molecular Therapeutics shared its third-quarter results, noting new trials for its 4D-150 product in eye diseases.

    Good for FDMT

    FDMT reported $375 million in cash, enough for its current plan into the second half of 2028. Trial progress supports a favorable read, though major results are still ahead.

  3. Oct 20, 2026, 8:14 AM ET · Market

    12 health care stocks are changing a lot before the market opens on Tuesday.

    Neutral

    4D Molecular Therapeutics shares fell 10.09% in Tuesday's premarket session. The article gives no company news to explain the fall, so it does not change the company's outlook.